Health Care Technology

Waystar

Waystar released FY2026 Q1 earnings on April 29 After-Market (EST), actual revenue USD 313.87 M (forecast USD 311.68 M), actual EPS USD 0.22 (forecast USD 0.1888)

Waystar to Release FY2026 Q1 Earnings on April 29 After-Market EST, Forecast Revenue USD 311.7 M, EPS USD 0.1888

Waystar Ranks First in Revenue Cycle Management AI Execution Customer Satisfaction Survey

Waystar released FY2025 annual earnings on February 17 Pre-Market (EST), actual revenue USD 1.099 B (forecast USD 1.09 B), actual EPS USD 0.61 (forecast USD 0.7052)

Waystar released FY2025 Q4 earnings on February 17 Pre-Market (EST), actual revenue USD 303.54 M (forecast USD 294.79 M), actual EPS USD 0.1029 (forecast USD 0.1875)

Waystar Reports 2025 Fiscal Year Revenue Growth of 16.5% to $1.1 Billion

Waystar to release FY2025 Q4 earnings on February 17, Pre-Market EST, forecast revenue USD 294.79 M, EPS USD 0.1875

Waystar stock price falls as Citi downgrades price target

UBS Analyst Gives Buy Rating to Waystar Holding Corp.

Waystar Holding Corp. CTO reports sale of common stock

Waystar CEO Matt Hawkins to Participate in Barclays 23rd Global Technology Conference

BMO Capital Markets Initiates BUY Rating on Waystar Holding Corp. with Price Target

Needham Analyst Ryan MacDonald Gives Waystar Holding Buy Rating and Price Target

Zacks Research Upgrades Waystar's Rating to 'Strong Buy'

Singh Recommends Healthcare Industry Stocks, Waystar Holding Reaffirmed with Buy Rating

Hotchkiss and Barclays Maintain Buy Rating on Waystar Holding

Waystar released FY2025 Q3 earnings on October 29 After-Market EST, actual revenue USD 268.65 M (forecast USD 257.83 M), actual EPS USD 0.17 (forecast USD 0.1513)

Waystar released FY2025 9 Months Earnings on October 29 After-Market EST, actual revenue USD 795.74 M, actual EPS USD 0.5099

Waystar Holding Corp. Reports Strong Q3 Earnings and Raises Full-Year Guidance

Kalia and TR | OpenAI Reiterate Buy Rating for Waystar Holding Corp.

Micware

Silexion Therapeutics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Linkage Global

GCL Global

Jupiter Neurosciences

Capstone

Arcadia Biosciences

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Waystar CEO Matt Hawkins will speak at the William Blair Growth Stock Conference on June 2, 2026, at 10:40 a.m. CT. This announcement was originally published by Waystar Holding Corp. via PR Newswire on May 20, 2026.

PUBT

Waystar CEO Hawkins speaks at William Blair Growth Stock Conference

FRPT

Analysts highlight three growth stocks this week: Waystar (WAY), Freshpet (FRPT), and Bilibili (BILI), all showing strong demand and improving fundamentals. Waystar, with a five-year revenue CAGR of 13.7%, is expected to grow by 18.61%, significantly above the sector average. It holds a Strong Buy consensus rating, with a price target suggesting a 73.85% upside.

Tip Ranks

FRESHPET

Bilibili

BILIBILI-W

3 Best Growth Stocks to Buy This Week, According to Analysts

BKKT

SNOW

U.S. stocks fell, with the Nasdaq down 1%. However, Waystar Holding shares surged 7.8% following a $200M stock repurchase plan. Other notable gainers included Agilysys (+29.9%), Bakkt (+18.5%), and Enhanced Group (+13.6%). Snowflake also saw a 6.3% increase, with a price target of $325 maintained by Citizens analyst Patrick Walravens.

benzinga_article

Bakkt

Snowflake

NASDAQ Composite Index

Agilysys

Enhanced

Hyperliquid Strategies

CCC Intelligent Solutions

PAR Tech

HubSpot

Yelp

Falcon Beyond Global

SAP AG-Sponsored

Asana

BAKKT INC C/WTS 25/10/2026 (TO PUR COM)

SAP SE

Waystar, Bakkt, Snowflake And Other Big Stocks Moving Higher On Tuesday

Waystar Announces $200 Million Share Repurchase Authorization, Reflecting Confidence in Long-Term Outlook | WAY Stock News

StockTitan

Waystar Announces $200 Million Share Repurchase Authorization, Reflecting Confidence in Long-Term Outlook | WAY Stock News

Waystar Named to TIME100 Most Influential Companies | WAY Stock News

Waystar Named to TIME100 Most Influential Companies | WAY Stock News

Waystar (NASDAQ:WAY) reached a new 52-week low of $20.35 after JPMorgan Chase downgraded its price target from $40 to $38, maintaining an overweight rating. The stock traded at $21.38 with a volume of over 8 million shares. Other analysts have also lowered their targets, with an average consensus price target of $36.38. Despite positive Q1 results, management indicated softer Q2 growth expectations, contributing to the stock's decline. Institutional investors have recently increased their holdings in Waystar, which has seen a 15.4% drop in stock price.

Market Beat

JPMorgan Chase

Evercore

Bank of Montreal

UBS Group AG

Wells Fargo

Antipodes Global Investment Company Ltd

First Horizon

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

Waystar (NASDAQ:WAY) Sets New 1-Year Low on Analyst Downgrade

OPCH

OSRH

ACHC

In Thursday's trading session, several health care stocks experienced significant movements. Akanda (AKAN) surged 64.1% to $42.65, while Picard Medical (PMI) rose 54.43% to $0.73. OSR Holdings (OSRH) increased by 51.43% to $0.70, and NewcelX (NCEL) gained 31.57% to $4.50. NovoCure (NVCR) and Glaukos (GKOS) also saw increases of 27.49% and 19.36%, respectively. Conversely, Option Care Health (OPCH) fell 29.7% to $18.89, with Enveric Biosciences (ENVB) down 25.97%. Acadia Healthcare (ACHC) and Waystar Holding (WAY) declined by 15.72% and 14.96%, respectively.

Option Care Health

Acadia Healthcare

Picard Medical

Akanda

NewcelX

Glaukos

iShares US Medical Devices

ALPS Medical Breakthrough

SPDR S&P Health

VG Health

SPDR S&P Health Equip

Health Care Select Sector SPDR

iShares Global Healthcare

iShares US Healthcare Providers

SPDR S&P Biotech

Novocure

Enveric Biosciences

Atlantic

Design Therapeutics

OSR HOLDINGS INC C/WTS 09/02/2028 (TO PUR COM)

NEWCELX LTD C/WTS 02/02/2026(TO PUR COM)

ATLANTIC INTERNATIONAL CORP C/WTS 31/08/2026 (TO PUR COM)

12 Health Care Stocks Moving In Thursday's Intraday Session

Earnings Watch

Waystar | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 313.87 M

William Blair analyst Ryan Daniels has maintained a Buy rating on Waystar (WAY) due to its strong Q1 performance, exceeding revenue and EBITDA expectations despite industry challenges. The company's leadership in AI-driven revenue cycle management and new product innovations are seen as growth drivers. With the stock trading at approximately 10x the 2027 EBITDA estimate, Daniels finds the risk/reward profile attractive. J.P. Morgan also supports this view with a Buy rating and a $40 price target.

TransMedics

HealthStream

Waystar: Buy Rating Backed by Strong Q1 Beat, AI-Driven RCM Leadership, and Attractive Risk/Reward Valuation

Waystar(WAY.US)

Waystar CEO Hawkins speaks at William Blair Growth Stock Conference

3 Best Growth Stocks to Buy This Week, According to Analysts

Waystar, Bakkt, Snowflake And Other Big Stocks Moving Higher On Tuesday

Waystar Announces $200 Million Share Repurchase Authorization, Reflecting Confidence in Long-Term Outlook | WAY Stock News

Waystar Named to TIME100 Most Influential Companies | WAY Stock News

Waystar (NASDAQ:WAY) Sets New 1-Year Low on Analyst Downgrade

12 Health Care Stocks Moving In Thursday's Intraday Session

Waystar | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 313.87 M

Waystar: Buy Rating Backed by Strong Q1 Beat, AI-Driven RCM Leadership, and Attractive Risk/Reward Valuation